Company
Headquarters: Melbourne, VIC, Australia
CEO: Dr. Donna L. Skerrett M.D., MS
A$159.9 Million
AUD as of Jan. 1, 2024
US$108.9 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema lesions, osteoarthritis, mucopolysaccharidosis, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Paradigm Biopharmaceuticals Limited has the following listings and related stock indices.
Stock: ASX: PAR wb_incandescent